Takeda’s Hyqvia Receives the US FDA Approval as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Shots:
- The company’s Hyqvia has been approved by the US FDA as maintenance therapy for adults with CIDP to prevent relapse of neuromuscular disability and impairment
- The approval was supported by the results from P-III (ADVANCE-CIDP 1) study investigating Hyqvia’s safety, efficacy and tolerability as maintenance therapy in adults with CIDP as well as the P-III (ADVANCE-CIDP 3) trial that enrolled patients who completed (ADVANCE-CIDP 1)
- The results from the (ADVANCE-CIDP 1) study in 122 evaluable CIDP patients on stable IVIG therapy revealed a difference of -18.3% in relapse rates b/w the Hyqvia (14.0%) vs PBO (32.3%) indicating Hyqvia's superiority in preventing CIDP relapse
Ref: Takeda | Image: Takeda
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
